01911-A: Enhanced Hemangiosarcoma Therapy Using a Novel Combination of Drugs That Target Tumor Proliferation

Grant Status: Open

Grant Amount: $12,873
Dr. Nicholas S. Duesbery, PhD, Van Andel Research Institute
February 1, 2013 - January 31, 2014
Breed(s): -All Dogs
Research Program Area: Oncology - Hemangiosarcoma

Abstract

Hemangiosarcoma (HSA) is a common canine cancer of blood vessels for which there are few treatment options. In previous research Dr. Andersen showed two different drugs, a mitogen-activated protein kinase kinase (MEK) inhibitor and a receptor tyrosine kinase (RTK) inhibitor, were effective in slowing the growth of HSA tumor cells. There is emerging evidence from human oncology that multiple drug targets are necessary to prevent drug resistance in cancer. Dr. Andersen's current objective is to test his previously evaluated drugs in combination in a rodent model of canine cancer. He hypothesizes that tumor size will be smaller in mice treated with both drugs then each drug alone. He further hypothesizes the combination treatment will have a longer duration and decrease drug failure rate compared to each drug alone. The long-term objective is to use this treatment in the clinic to treat dogs with HSA.

Publication(s)

None at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Make an Investment Today:

  • $40
  • $60
  • $100
  • $250
  • Give Now
Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2016 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software